Viability-reducing activity of Coryllus avellana L. extracts against human cancer cell lines

dc.contributor.authorGallego, Ana
dc.contributor.authorMetón Teijeiro, Isidoro
dc.contributor.authorBaanante, Isabel V.
dc.contributor.authorOuazzani, Jamal
dc.contributor.authorAdelin, Amelie
dc.contributor.authorPalazón Barandela, Javier
dc.contributor.authorBonfill Baldrich, Ma. Mercedes
dc.contributor.authorMoyano Claramunt, Elisabet
dc.date.accessioned2020-06-17T07:52:26Z
dc.date.available2020-06-17T07:52:26Z
dc.date.issued2017-03-01
dc.date.updated2020-06-17T07:52:26Z
dc.description.abstractThe increasing rate of cancer incidence has encouraged the search for novel natural sources of anticancer compounds. The presence of small quantities of taxol and taxanes in Corylus avellana L. has impelled new potential applications for this plant in the field of biomedicine. In the present work, the cell viability-reducing activity of stems and leaves from three different hazel trees was studied against three human-derived cancer cell lines (HeLa, HepG2 and MCF-7). Both leaf and stem extracts significantly reduced viability of the three cell lines either after maceration with methanol or using taxane extraction methods. Since maceration reduced cell viability to a greater extent than taxane extraction methods, we scaled up the maceration extraction process using a method for solid/liquid extraction (Zippertex technology). Methanol leaf extracts promoted a higher reduction in viability of all cell lines assayed than stem extracts. Fractionation of methanol leaf extracts using silica gel chromatography led to the purification and identification of two compounds by HPLC-MS and NMR: (3R,5R)-3,5-dihydroxy-1,7-bis(4-hydroxyphenyl) heptane 3-O-β-d-glucopyranoside and quercetin-3-O-rhamnoside. The isolated compounds decreased viability of HeLa and HepG2 cells to a greater extent than MCF-7 cells. Our results suggest a potential use of C. avellana extracts in the pharmacotherapy of cervical cancer and hepatocarcinoma and, to a lesser extent, breast cancer.
dc.format.extent8 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec668770
dc.identifier.issn0753-3322
dc.identifier.urihttps://hdl.handle.net/2445/165960
dc.language.isoeng
dc.publisherElsevier Masson SAS
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1016/j.biopha.2017.02.046
dc.relation.ispartofBiomedicine & Pharmacotherapy, 2017, vol. 89, p. 565-572
dc.relation.urihttps://doi.org/10.1016/j.biopha.2017.02.046
dc.rights(c) Elsevier Masson SAS, 2017
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.sourceArticles publicats en revistes (Bioquímica i Fisiologia)
dc.subject.classificationFarmacologia
dc.subject.classificationQuímica
dc.subject.classificationCèl·lules canceroses
dc.subject.classificationAvellaner
dc.subject.classificationCàncer
dc.subject.classificationCromatografia de líquids d'alta resolució
dc.subject.otherPharmacology
dc.subject.otherChemistry
dc.subject.otherCancer cells
dc.subject.otherHazel
dc.subject.otherCancer
dc.subject.otherHigh performance liquid chromatography
dc.titleViability-reducing activity of Coryllus avellana L. extracts against human cancer cell lines
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/acceptedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
668770.pdf
Mida:
971.93 KB
Format:
Adobe Portable Document Format